The Affiliated Hospital of Xuzhou Medical University

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

4 drugs in development

Approved1

Phase 21

Phase 11

Preclinical1

By Therapeutic Area

top 3

Oncology

360%

Cardiovascular

120%

Immunology

120%

R&D Momentum

59/100

Pipeline Velocity

34/100

Trial Completion Rate

100/100

Pipeline Concentration

44/100

Pipeline Freshness

66/100

Strategic Signals

↗Active in Cardiovascular but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Completed

Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled Trial

Jul 3, 2026

Recruiting

A Prospective, Phase II Clinical Study Protocol of Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)

Earlier

Mar 17, 2026TrialEfficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)

Mar 1, 2026TrialUCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases

Nov 20, 2025TrialEffectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

Nov 12, 2025TrialAT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study

Oct 30, 2025TrialEvaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke

Sep 1, 2025TrialApplication of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders.

4 more events

Sep 1, 2025TrialApplication of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

Aug 1, 2025TrialTislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

May 1, 2025TrialIparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

Apr 1, 2025TrialTislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)